

December 30, 2024

Company Name : Veritas In Silico Inc.
Representative : Shingo NAKAMURA
Representative Director and CEO
Listed on : TSE Growth
Stock Ticker Code : 130A
Contact Person : Hiroaki HAGIWARA
Director and General Manager,
Administration Division
Email: ir@veritasinsilico.com

Patent owned by Veritas In Silico to Become Effective in Europe

Veritas In Silico Inc. has announced that one of its patents, "METHOD FOR SCREENING COMPOUND FOR CONTROLLING RNA FUNCTION " is scheduled to be listed in "European Patent Bulletin No. 25/01." The patent, which was registered in Japan in September 2020, is currently being processed in the European Patent Organization and will become effective on January 1st, 2025.

- Title of Invention: METHOD FOR SCREENING COMPOUND FOR CONTROLLING RNA FUNCTION
- Application Number: 19768245.3
(International Application Number: PCT/JP2019/010571)
- Filing Date: March 14, 2019
- Patent Number: 3766989
- Patent Holder: Veritas In Silico Inc.

The patent covers the analysis of substructures and existence probabilities inherent in target mRNAs, the identification of substructures with appropriate existence probabilities as drug targets, and screening methods using the substructures selected as drug targets. These are the basis of the Company's mRNA-targeted small molecule drug discovery.

This patent application is one of the key strategies to globalize the Company's fundamental technologies and will strengthen the technology for use on the Company's proprietary drug discovery platform, ibVIS®.

The patent acquisition will have a negligible impact on its business performance. The Company is certain that it will contribute to making significant progress in its business in the future.